Quidel Corporation (NASDAQ: QDEL), a leading provider of point-of-care rapid diagnostic tests, announced today that John D. Tamerius, Ph.D., currently vice president, clinical/regulatory affairs, has been promoted to senior vice president, clinical/regulatory affairs, effective November 10, 2008.
“It is a pleasure to recognize John’s expertise and success by naming him senior vice president, clinical/regulatory affairs. Under his leadership, the company has developed strong relationships with key thought leaders in the medical community and improved the clinical efficacy of our products. John’s promotion is well deserved,” said Caren Mason, president and chief executive officer of Quidel Corporation.
Dr. Tamerius has been an integral part of Quidel for 25 years. He has served as vice president, clinical/regulatory affairs since 2005, and previously held a variety of executive roles including responsibility for research and development and general management of Northern California operations.
Dr. Tamerius originally joined Quidel in 1983 with the acquisition of Cytotech, Inc. where he was president. Prior to working at Cytotech, Dr. Tamerius was a research associate at Scripps Clinic and Research Foundation. Dr. Tamerius has been awarded a Bachelor of Science, a Master of Science, and a Ph.D. in Microbiology and Immunology, all from the University of Washington.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel’s portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel’s products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel’s Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.flutest.com, www.quidel.com, or www.colorectal-test.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the timing of onset, length and severity of cold and flu seasons, uncertainty surrounding the detection of novel influenza viruses involving human specimens, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors and the level of success in our recent distributor incentive programs, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration (the “FDA”), intellectual property, product liability, environmental or other litigation, required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower-than-anticipated sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as “may,””will,””should,””might,””expect,””anticipate,””estimate,” and similar words, although some forward-looking statements are expressed differently. The risks described under “Risk Factors” in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements.
Comments